Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/ed/10/97/ed109781-fdcf-54a1-2ca8-12cdaab3aa74/mza_10884420270014206222.png/600x600bb.jpg
NewsRamp Science, Exploration and Discovery Podcast
NewsRamp
249 episodes
2 days ago
Explore the wonders of science with the 'NewsRamp Science Podcast.' Each episode offers the latest news and detailed summaries from NewsRamp.com, covering scientific breakthroughs, research advancements, and technological innovations. Stay informed on the discoveries that shape our understanding of the world.
Show more...
Science
RSS
All content for NewsRamp Science, Exploration and Discovery Podcast is the property of NewsRamp and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Explore the wonders of science with the 'NewsRamp Science Podcast.' Each episode offers the latest news and detailed summaries from NewsRamp.com, covering scientific breakthroughs, research advancements, and technological innovations. Stay informed on the discoveries that shape our understanding of the world.
Show more...
Science
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/ed/10/97/ed109781-fdcf-54a1-2ca8-12cdaab3aa74/mza_10884420270014206222.png/600x600bb.jpg
Soligenix Inc.'s Breakthrough in Dermatology Market with SGX302 for Psoriasis
NewsRamp Science, Exploration and Discovery Podcast
2 minutes
3 days ago
Soligenix Inc.'s Breakthrough in Dermatology Market with SGX302 for Psoriasis
Soligenix Inc., trading as SNGX on NASDAQ, is advancing in the dermatology sector with SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis. Early phase 2a trial results indicate promising safety and efficacy, positioning SGX302 as a potential well-tolerated treatment for psoriasis. Soligenix aims to capitalize on the growing $67 billion market opportunity by expanding its presence in dermatology, with ongoing trials potentially leading to regulatory approval and commercialization, highlighting the company's dedication to addressing unmet medical needs in rare diseases.
NewsRamp Science, Exploration and Discovery Podcast
Explore the wonders of science with the 'NewsRamp Science Podcast.' Each episode offers the latest news and detailed summaries from NewsRamp.com, covering scientific breakthroughs, research advancements, and technological innovations. Stay informed on the discoveries that shape our understanding of the world.